Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in “freeze-all” approach

References

• Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update. 2003; Jan-Feb9(1):1–6.
   PubMed Web of Science ®Google Scholar
• Pellicer N, Galliano D, Pellicer A. Chapter 22 - Ovarian hyperstimulation syndrome. In: leung PCK, Adashi EY, editors. The ovary. (Third Edition): Cambridge, MA: Academic Press; 2019. p. 345–362.
   Google Scholar
• Steward RG, Lan L, Shah AA, et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril. 2014; Apr101(4):967–973.
   PubMed Web of Science ®Google Scholar
• Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006; Jan85(1):112–120.
   PubMed Web of Science ®Google Scholar
• Griesinger G, Verweij PJ, Gates D, et al. Prediction of ovarian hyperstimulation syndrome in patients treated with corifollitropin alfa or rFSH in a GnRH antagonist protocol. PLoS One. 2016;11(3):e0149615.
   PubMed Web of Science ®Google Scholar
• Soares SR, Gomez R, Simon C, et al. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008; Jul-Aug14(4):321–333.
   PubMed Web of Science ®Google Scholar
• Shapiro BS, Daneshmand ST, Garner FC, et al. Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization. Fertil Steril. 2005; Jul84(1):93–98.
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002; Nov-Dec8(6):559–577.
   PubMed Web of Science ®Google Scholar
• D’Angelo A, Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2007; Jul 18(3):CD002806.
   Google Scholar
• , Bosch E, Broer S, The ESHRE Guideline Group On Ovarian Stimulation, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI(dagger). Hum Reprod Open. 2020;2020(2):hoaa009.
   PubMedGoogle Scholar
• Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod. 2000; Sep15(9):1965–1968.
   PubMed Web of Science ®Google Scholar
• Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014; Oct 31(10):CD008046.
   Google Scholar
• Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2004; Jan81(1):1–5.
   PubMed Web of Science ®Google Scholar
• Miller I, Chuderland D, Ron-El R, et al. GnRH agonist triggering modulates PEDF to VEGF ratio inversely to hCG in granulosa cells. J Clin Endocrinol Metab. 2015; Nov100(11):E1428–36.
   PubMed Web of Science ®Google Scholar
• Fauser BC, de Jong D, Olivennes F, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002; Feb87(2):709–715.
   PubMed Web of Science ®Google Scholar
• Devroey P, Polyzos NP, Blockeel C. An OHSS-Free clinic by segmentation of IVF treatment. Hum Reprod. 2011; Oct26(10):2593–2597.
   PubMed Web of Science ®Google Scholar
• Ling LP, Phoon JW, Lau MS, et al. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at ‘freeze-all strategy. Reprod Biomed Online. 2014; Sep29(3):392–394.
   PubMed Web of Science ®Google Scholar
• Gurbuz AS, Gode F, Ozcimen N, et al. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod Biomed Online. 2014; Nov29(5):541–544.
   PubMed Web of Science ®Google Scholar
• Orvieto R, Vanni VS. Ovarian hyperstimulation syndrome following GnRH agonist trigger-think ectopic. J Assist Reprod Genet. 2017; Sep34(9):1161–1165.
   PubMed Web of Science ®Google Scholar
• Nyboe Andersen A, Nelson SM, Fauser BC, et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017; Feb107(2):387–396 e4.
   PubMed Web of Science ®Google Scholar
• Bosch E, Havelock J, Martin FS, et al. Follitropin Delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind phase 3 safety trial. Reprod Biomed Online. 2019; Feb38(2):195–205.
   PubMed Web of Science ®Google Scholar
• Ishihara O, Arce JC, Japanese Follitropin Delta Phase 3 Trial G Individualized follitropin Delta dosing reduces OHSS risk in japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021 May;42(5):909–918.
   PubMed Web of Science ®Google Scholar
• Qiao J, Zhang Y, Liang X, et al. A randomised controlled trial to clinically validate follitropin Delta in its individualised dosing regimen for ovarian stimulation in asian IVF/ICSI patients. Hum Reprod. 2021; Aug 1836(9):2452–2462.
   PubMed Web of Science ®Google Scholar
• Golan A, Ron-el R, Herman A, et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989; Jun44(6):430–440.
   PubMedGoogle Scholar
• Fernandez-Sanchez M, Visnova H, Yuzpe A, et al. Individualization of the starting dose of follitropin Delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles. Reprod Biomed Online. 2019; Apr38(4):528–537.
   PubMed Web of Science ®Google Scholar
• Garcia-Velasco JA. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertil Steril. 2012; Mar97(3):527–528.
   PubMed Web of Science ®Google Scholar
• Pabuccu EG, Pabuccu R, Caglar GS, et al. Different gonadotropin releasing hormone agonist doses for the final oocyte maturation in high-responder patients undergoing in vitro fertilization/intra-cytoplasmic sperm injection. J Hum Reprod Sci. 2015; Jan-Mar8(1):25–29.
   PubMedGoogle Scholar
• Vuong TN, Ho MT, Ha TD, et al. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertil Steril. 2016; Feb105(2):356–363.
   PubMed Web of Science ®Google Scholar
• Popovic-Todorovic B, Santos-Ribeiro S, Drakopoulos P, et al. Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation. Hum Reprod. 2019; Oct 234(10):2027–2035.
   PubMed Web of Science ®Google Scholar
• Fatemi HM, Garcia-Velasco J. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fertil Steril. 2015; Apr103(4):870–873.
   PubMed Web of Science ®Google Scholar
• Lawrenz B, Ruiz F, Engelmann N, et al. Individual luteolysis post GnRH-agonist-trigger in GnRH-antagonist protocols. Gynecol Endocrinol. 2017; Apr33(4):261–264.
   PubMed Web of Science ®Google Scholar
• Busso C, Fernandez-Sanchez M, Garcia-Velasco JA, et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod. 2010; Apr25(4):995–1004.
   PubMed Web of Science ®Google Scholar
• Tang H, Mourad SM, Wang A, et al. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2021; Apr 144(4):CD008605.
   PubMedGoogle Scholar
• Royal College of Obstetricians & Gynecologists. The management of ovarian hyperstimulation syndrome. Green-top Guideline No. 5. 2016.
   Google Scholar
• Pfeifer S, Butts S, Dumesic D, et al. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertility and Sterility. 2016;106(7):1634–1647.
   PubMed Web of Science ®Google Scholar
• Castillo JC, Haahr T, Martinez-Moya M, et al. Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer. Ups J Med Sci. 2020; May125(2):131–137.
   PubMed Web of Science ®Google Scholar
• Kol S, Humaidan P. LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango? Reprod Biomed Online. 2010; Nov21(5):590–592.
   PubMed Web of Science ®Google Scholar
• Lamb JD, Shen S, McCulloch C, et al. Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2011; Apr95(5):1655–1660.
   PubMed Web of Science ®Google Scholar